---
figid: PMC7840349__cmj-57-36-g002
figtitle: Recent Updates of Lipoprotein(a) and Cardiovascular Disease
organisms:
- NA
pmcid: PMC7840349
filename: cmj-57-36-g002.jpg
figlink: /pmc/articles/PMC7840349/figure/F2/
number: F2
caption: 'Pathogenicity of Lp(a). The pathogenicity of Lp(a) can be roughly divided
  into three categories: atherosclerosis, inflammation and thrombosis. The main pathological
  mechanisms of each category are listed in this figure. TFPI: tissue factor pathway
  inhibitor, SMC: smooth muscle cell, EC: endothelial cell. Created with BioRender.com.'
papertitle: Recent Updates of Lipoprotein(a) and Cardiovascular Disease.
reftext: Taili Liu, et al. Chonnam Med J. 2021 Jan;57(1):36-43.
year: '2021'
doi: 10.4068/cmj.2021.57.1.36
journal_title: Chonnam Medical Journal
journal_nlm_ta: Chonnam Med J
publisher_name: Chonnam National University Medical School
keywords: Atherosclerosis | Lipids | Cardiovascular Diseases
automl_pathway: 0.68401
figid_alias: PMC7840349__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7840349__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7840349__cmj-57-36-g002.html
  '@type': Dataset
  description: 'Pathogenicity of Lp(a). The pathogenicity of Lp(a) can be roughly
    divided into three categories: atherosclerosis, inflammation and thrombosis. The
    main pathological mechanisms of each category are listed in this figure. TFPI:
    tissue factor pathway inhibitor, SMC: smooth muscle cell, EC: endothelial cell.
    Created with BioRender.com.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PLG
  - FGA
  - FGB
  - FGG
  - TFPI
  - APOA1
  - APOB
  - ERVK-8
  - ERVK-10
  - ERVK-9
  - ERVK-21
  - ERVK-18
  - ERVK-25
  - ERVK-24
  - ERVK-19
  - DYM
  - TEC
---
